Development of a novel cancer vaccine utilizing liposomes modified with complement activation polymer
| Project/Area Number |
15K18921
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
SHIMIZU Taro 徳島大学, 大学院医歯薬学研究部(薬学系), 特任助教 (30749388)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | ワクチン / 抗原送達 / 補体 / リポソーム / 辺縁帯B細胞 / 癌 / 免疫学 |
|---|
| Outline of Final Research Achievements |
In this study, we tried to develop a novel type antigen delivery system. We focused on polymer-conjugated liposome that can activate complement system in order to deliver antigen to splenic marginal zone B cells. Widely-used conjugation polymer is polyethylene glycol (PEG) with methoxy terminal group (methoxy PEG). We found that hydroxyl PEG-conjugated liposomes spontaneously activated complement system and were selectively delivered to marginal zone B cells. Encapsulation of antigen and adjuvant into hydroxyl PEG-conjugated liposomes enhanced antigen-specific immune response. These results indicate that hydroxyl PEG-conjugated liposomes, which enable antigen delivery to marginal zone B cells, are novel antigen delivery system.
|
Report
(3 results)
Research Products
(10 results)
